Agenus (NASDAQ:AGEN - Get Free Report) had its price target reduced by analysts at Robert W. Baird from $6.00 to $3.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has a "neutral" rating on the biotechnology company's stock. Robert W. Baird's price objective would suggest a potential upside of 61.29% from the company's current price.
Separately, HC Wainwright restated a "neutral" rating on shares of Agenus in a report on Wednesday. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $8.75.
Get Our Latest Analysis on Agenus
Agenus Stock Performance
Agenus stock traded up $0.19 during midday trading on Wednesday, reaching $1.86. The company's stock had a trading volume of 939,829 shares, compared to its average volume of 415,827. The stock's 50 day simple moving average is $3.23 and its 200 day simple moving average is $3.84. Agenus has a fifty-two week low of $1.65 and a fifty-two week high of $19.69. The firm has a market capitalization of $43.63 million, a PE ratio of -0.17 and a beta of 1.23.
Agenus (NASDAQ:AGEN - Get Free Report) last released its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.36) by $0.32. The firm had revenue of $26.84 million for the quarter, compared to analyst estimates of $30.09 million. Equities analysts predict that Agenus will post -12.55 earnings per share for the current year.
Hedge Funds Weigh In On Agenus
Several large investors have recently added to or reduced their stakes in AGEN. Corton Capital Inc. bought a new stake in shares of Agenus in the 4th quarter worth approximately $36,000. Virtu Financial LLC acquired a new stake in Agenus in the fourth quarter worth about $51,000. Apollon Wealth Management LLC acquired a new position in shares of Agenus during the fourth quarter valued at approximately $55,000. EP Wealth Advisors LLC acquired a new position in shares of Agenus during the 3rd quarter valued at $55,000. Finally, Bank of Montreal Can bought a new stake in shares of Agenus in the 4th quarter worth $69,000. 61.46% of the stock is currently owned by institutional investors.
About Agenus
(
Get Free Report)
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Featured Articles
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
